China Pharma Holdings, Inc. (NYSE:CPHI – Get Free Report)’s share price traded up 1.2% during mid-day trading on Thursday . The company traded as high as $0.8239 and last traded at $0.7620. 23,100 shares changed hands during mid-day trading, a decline of 88% from the average session volume of 197,867 shares. The stock had previously closed at $0.7526.
China Pharma Stock Performance
The business’s fifty day simple moving average is $0.67 and its 200-day simple moving average is $0.98. The firm has a market cap of $31.69 million, a P/E ratio of -1.42 and a beta of 0.99. The company has a current ratio of 0.79, a quick ratio of 0.26 and a debt-to-equity ratio of 0.22.
Institutional Investors Weigh In On China Pharma
A hedge fund recently raised its stake in China Pharma stock. Citadel Advisors LLC grew its stake in shares of China Pharma Holdings, Inc. (NYSE:CPHI – Free Report) by 31.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,426 shares of the company’s stock after purchasing an additional 7,356 shares during the period. Citadel Advisors LLC owned approximately 0.93% of China Pharma worth $59,000 as of its most recent SEC filing.
About China Pharma
China Pharma Holdings, Inc develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.
Recommended Stories
- Five stocks we like better than China Pharma
- Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem
- These 3 Software Stocks Are Buying Back Shares Hand Over Fist
- Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%
- MongoDB’s AI Advantage Is Starting to Show Up in Results
Receive News & Ratings for China Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
